SOURCE: Acceleron Equity Research

January 27, 2015 04:00 ET

Updated Coverage Report Focuses on Pluristem Therapeutics

NEW YORK, NY--(Marketwired - Jan 27, 2015) - Pluristem Therapuetics (NASDAQ: PSTI) is the subject of an updated coverage report by Acceleron Equity Research, a stock market research firm focused on emerging companies and technologies.

Interested investors may get more information and a copy of the coverage report at:

PSTI is accelerating time to market approval for its first indication. On January 12, 2015 PSTI announced its focus for 2015 includes making significant progress in its clinical pipeline and shortening the time to market for its first product. PSTI expects the first marketing approval for its PLX cells would be for critical limb ischemia and/or hematological indications. PSTI has not yet stated a timeline for approval; however, we expect there may be significant progress towards this event in 2015, given that PSTI is already conducting a Phase 2 trial in Europe. The EU's new Adaptive Licensing legislation allows for limited commercialization of cell therapy products after a successful Phase 2 trial. A similar law which came into effect in Japan in November 2014 allows conditional approval for cell therapies after limited proof of efficacy. PSTI is active in Japan's market where it is well positioned for a licensing deal.

PSTI addresses 5 clinical areas that collectively address a market over $27.5 billion. On October 21, 2014 PSTI announced it has advanced its second major cell line, PLX-R18 into large-scale manufacturing. PLX-R18 is developed to treat hematologic conditions including bone marrow deficiency resulting from blood cancers, as well as acute radiation syndrome. The global blood disorders market segment is an estimated $50 billion market and PLX-R18 addresses a substantial portion of this market. This is in addition to the $27.5 billion market for cardiovascular, orthopedic, pulmonary, and pregnancy indications that PSTI's first therapeutic cell line, PLX-PAD addresses.

PSTI has a robust IP portfolio that leads the cell therapy industry. On October 7, 2014 PSTI announced that one of its patents covering cells derived from the placenta was upheld at the European Patent Office after being challenged. The fact that the patent was challenged and upheld makes it stronger and shows PSTI is highly committed to having the most robust IP in the cell therapy space. The Company now has 34 granted patents and over 120 pending applications worldwide. In the past three months alone PSTI has been granted four patents.

PSTI is advancing into Phase 2/3 trials in 2 indications. PSTI just reported on January 12, 2014 that it will progress into Phase 2/3 trials in an orthopedic indication. This is based on the outstanding results of its completed Phase 2 trial in muscle injury in Germany, which showed PLX cells had a 500% improvement in muscle force over placebo. The Company also plans to initiate Phase 2/3 trials in Europe and/or Japan for the treatment of critical limb ischemia.

About Acceleron Equity Research
Acceleron is a market intelligence service that focuses on identifying and analyzing technically-complicated companies and equities. Acceleron offers a subscription model product to investors and funds with an emphasis in the emerging markets.

Contact Information

  • Media Only Contact:

    M. Morhamus
    Acceleron Equity Research